Company Overview
Emergent BioSolutions Inc. operates as a life sciences company dedicated to providing preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats across the United States, Canada, and international markets. The company functions within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, positioning it as a critical player in the biodefense and public health infrastructure landscape. In terms of scale, the entity manages a market capitalization of $431.19M while generating annual revenue of $742.90M and employing approximately 900 individuals. These valuation and revenue figures indicate that the company maintains a significant operational footprint within a niche market, leveraging its workforce to deliver specialized products through its Commercial Products, MCM Products, and All Other Revenues segments to address complex global health challenges.
Financial Health
The company reported a revenue of $742.90M and net income of $52.60M for the trailing twelve months, with an EBITDA of $208.90M. The substantial gap between the $742.90M revenue and the $52.60M net income reveals a cost structure where operating expenses and other costs consume a significant portion of top-line growth before reaching the bottom line. Free cash flow stands at $205.39M, which provides the organization with substantial financial flexibility to fund operations, invest in research and development, or manage capital expenditures without immediate reliance on external financing. The company reports a gross margin of 49.4%, indicating strong pricing power or high-value specialized manufacturing costs relative to sales. However, the operating margin is reported at -15.2%, suggesting that overhead costs currently exceed operating revenue, while the profit margin sits at 7.1%, reflecting the final profitability after all expenses. On the balance sheet, total cash assets amount to $205.40M, whereas total debt obligations reach $583.70M, resulting in a debt-to-equity ratio of 111.69 which characterizes the company as highly leveraged rather than conservative. Despite the high leverage, the current ratio is an impressive 5.01, indicating robust short-term liquidity and the ability to meet immediate financial obligations with ease. Return on equity is calculated at 10.5% and return on assets at 5.3%, metrics that reveal management is generating returns on shareholder capital and total assets, albeit with varying efficiency levels relative to the asset base.
Valuation Assessment
Emergent BioSolutions Inc. trades with a trailing P/E ratio of 8.83 and a forward P/E of 2.75. The significant disparity between these two multiples implies that the market expects a substantial increase in future earnings that will compress the valuation multiple over time, suggesting a potential re-rating if performance meets high growth expectations. The price-to-book ratio is 0.82, which indicates that the market values the company at less than its book value, signaling a discount relative to the net asset position or reflecting concerns about future profitability. Alternative valuation metrics such as the price-to-sales ratio of 0.58 and an EV/EBITDA of 3.85 suggest the stock is priced at a discount relative to sales and earnings generation compared to typical peers in the specialty drug sector. Price action over the last year has seen the stock fluctuate between a 52-week high of $14.06 and a 52-week low of $4.02. Without the current specific share price provided in the input data to calculate an exact percentage, the valuation context relies heavily on these historical extremes which define the trading range for risk assessment. The beta value is 2.44, which means the stock price is expected to be significantly more volatile than the broader market, amplifying gains during bull runs and losses during market corrections.
Growth & Income
Revenue growth year-over-year is recorded at -23.6%, while earnings growth for the period is marked as N/A. The negative revenue growth indicates a contraction in top-line sales, and since earnings data is not available for this period, the implication is that the company is navigating a challenging revenue environment that impacts overall profitability. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all of its earnings back into the business operations rather than distributing cash to shareholders. This approach suggests a focus on internal funding for growth initiatives or debt management rather than providing a regular income stream to investors. The overall growth and income profile for Emergent BioSolutions Inc. is characterized by a contraction in revenue with no dividend support, reflecting a capital-intensive growth phase or a period of market adjustment rather than a mature cash cow status.